Disclaimer: This is a recording from Bitesize Bio, which was originally recorded in the United Kingdom; the references to “Merck” within refer to (1) Merck KGaA, Darmstadt, Germany; (2) an affiliate of Merck KGaA, Darmstadt, Germany; or (3) one of the businesses of Merck KGaA, Darmstadt, Germany, which operate in the U.S. and Canada as EMD Serono in Healthcare, MilliporeSigma in Life Science and EMD Electronics in Electronics.
For further information about our names in the U.S. and Canada and internationally, please refer to our disclaimer at emdgroup.com
Multi-target screening can offer great insight into the genetic pathways involved in drug resistance and disease. RNAi and the fast pace of CRISPR technology development have brought sophisticated options for library screens, including the possibility of genome-wide pooled and arrayed screens for knockdown, knockout, knock-in and gene modulation. shRNA and CRISPRi allow for targeted suppression of gene function, while ORFs and CRISPRa offer a gain-of-function approach to screening. Both complement existing loss-of-function technologies such as efficient knockout using traditional CRISPR-Cas9. It is now also possible to take your screening to single-cell resolution using 10x Genomics compatible CRISPR guide vectors.
In this webinar, you will discover:
Gurpreet Balrey, Ph.D.
Merck KGaA, Darmstadt, Germany
Head of Global Commercial Enablement and EMEA Business Head
Session 1:presented October 13, 2021
To continue reading please sign in or create an account.Don't Have An Account?